Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

Ingrid A. Mayer*, Fengmin Zhao, Carlos L. Arteaga, William F. Symmans, Ben H. Park, Brian L. Burnette, Amye J. Tevaarwerk, Sofia F. Garcia, Karen L. Smith, Della F. Makower, Margaret Block, Kimberly A. Morley, Chirag R. Jani, Craig Mescher, Shabana J. Dewani, Bernard Tawfik, Lisa E. Flaum, Erica L. Mayer, William M. Sikov, Eve T. RodlerLynne I. Wagner, Angela M. DeMichele, Joseph A. Sparano, Antonio C. Wolff, Kathy D. Miller

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

89 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science